Black Rock Inc. Biocryst Pharmaceuticals Inc Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
260Shares Held
174MCall Options Held
397KPut Options Held
444K-
Vanguard Group Inc Valley Forge, PA18.8MShares$153 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$102 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$76.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$71.9 Million4.25% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$66.3 Million1.06% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.52B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...